Discovery

Explore Topics Papers

Docs Terms Privacy

Search Kritoma

Recent searches

Searches you run from this bar will appear here.

CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Knowledge Timeline Gaps (1)Evidence (307)Community (0)

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

249 papers

SearchSort evidence

All307 Core249 Supporting83 Background0

Active filtersClassification:Core

Showing 145-156 of total 249 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Biomarker-driven immunotherapy and adoptive cell therapy in recurrent pancreatic ductal adenocarcinoma.

He T; Li G; Qi F

Jan 1, 2026

Frontiers in medicine

2026PubMedDirectly related

Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach.

Sandoval-Castellanos AM; Ahn YR; Canter RJ; Brown EG; Kim J

Jan 1, 2026Progress in biomedical engineering (Bristol, England)

2026PubMedDirectly related

Functional genomics-guided design of CAR-T and CAR-NK therapies in hematological malignancies: aligning cellular engineering with immune escape and microenvironmental resistance.

Cai S; Tan Y; Yang Q; Huang J

Jan 1, 2026Frontiers in genome editing

2026PubMedDirectly related

CAR-T cell therapy: potential for paediatric brain tumours-an update.

Zehner A; Draper B; Hargrave D; Donovan LK; Anderson J

Jan 1, 2026Journal of neuro-oncology

2026PubMedDirectly related

Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma.

Adeshakin AO; Shi H; Perry SS; Sheppard H; Nguyen P; Sun X; Zhou P; Métais JY; Cunningham T; Kc A; Tian L; Peche V; Prater MS; Langfitt DM; O'Reilly C; Park JJ; Chabot A; Zhou S; Matsubara A; Lee G; Tsai SQ; Pruett-Miller SM; Talbot LJ; Yustein JT; Krenciute G; DeRenzo C; Chi H; Gottschalk S

Jan 1, 2026Cell reports. Medicine

2026PubMedDirectly related

Antigen-presenting nanoparticles for in vivo CAR T cell engineering.

Su FI

Jan 1, 2026Nature reviews bioengineering

2026PubMedDirectly related

Cell-Type-Tailored Hydrogels for Adoptive Cell Therapy in Cancer.

Shin JH; Song Y; Park J

Jan 1, 2026Gels (Basel, Switzerland)

2026PubMedDirectly related

Breathing new life into T-cell receptor-engineered T-cell therapy in solid tumors: enhancing strategies to expand the universality of precision therapy.

Li Y; Zhang X; Chen Y; Lin J; Liang T; Bai X

Jan 1, 2026Experimental hematology & oncology

2026PubMedDirectly related

Structure-Function Insights into Immune Receptors Drive Innovation in CAR-T Cell Therapy.

Xia T; Wei C; Chen X

Jan 1, 2026Current issues in molecular biology

2026PubMedDirectly related

Co-delivery of lentiviral vectors and Cas9-containing virus-like particles enables rapid, scalable manufacture of gene-edited CAR T cells.

Ferrara F; Wielgosz MM; Park JJ; Bauler M; Wincek C; Mier N; Su Y; Tang L; Lowe BR; Beard JA; Langfitt DM; Zhou S; Throm RE

Jan 1, 2026Molecular therapy. Advances

2026PubMedDirectly related

Engineering a Second Interchain Disulfide Bond in the αβ T-Cell Receptor Constant Domain: A Powerful Strategy to Enhance Stability, Pairing Fidelity, and Therapeutic Efficacy in TCR-T Cell Therapy.

Quan NT; Lin X; Xuan DTN; Anh BTV

Jan 1, 2026Pharmaceuticals (Basel, Switzerland)

2026PubMedDirectly related

NF-κB/NFAT signaling contributes to B7-H3 TRuC-T cell cytotoxicity and supports a reporter platform for glioblastoma immunotherapy.

Lin J; Zhang P; Li X; Lu S; Yu Q; Zheng J; Yang J; Chen X; Wei C; Gao J; Zhao A

Jan 1, 2026Frontiers in immunology

Page 13 of 21Showing 145-156 of total 249 results.

1...121314...21

CAR-T and engineered T cell therapies — Research Evidence and Topic Memory | Kritoma